Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 850671, 3 pages
http://dx.doi.org/10.1155/2015/850671
Editorial

Enhanced Cardiovascular Risk in Rheumatoid Arthritis: Elucidation, Assessment, and Management

1Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg 2193, South Africa
2Preventive Cardio-Rheuma Clinic, Department of Rheumatology, Diakonhjemmet Hospital, 0370 Oslo, Norway
3Department of Rheumatology, Hospital Universitario Marques de Valdecilla, IDIVAL, 39008 Santander, Spain
4Department of Rheumatology, Radboud University Nijmegen Medical Centre, 6525 Nijmegen, Netherlands

Received 23 December 2014; Accepted 23 December 2014

Copyright © 2015 Patrick H. Dessein et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. A. Gonzalez-Gay, C. Gonzalez-Juanatey, and J. Martin, “Rheumatoid arthritis: a disease associated with accelerated atherogenesis,” Seminars in Arthritis and Rheumatism, vol. 35, no. 1, pp. 8–17, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. P. H. Dessein, G. R. Norton, A. J. Woodiwiss, B. I. Joffe, and F. Wolfe, “Influence of nonclassical cardiovascular-risk factors on the accuracy of predicting subclinical atherosclerosis in rheumatoid arthritis,” Journal of Rheumatology, vol. 34, no. 5, pp. 943–951, 2007. View at Google Scholar · View at Scopus
  3. M. A. Gonzalez-Gay, C. Gonzalez-Juanatey, M. J. Lopez-Diaz et al., “HLA-DRB1 and persistent chronic inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis,” Arthritis Care & Research, vol. 57, no. 1, pp. 125–132, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. L. Rodríguez-Rodríguez, R. López-Mejías, M. García-Bermúdez, C. González-Juanatey, M. A. González-Gay, and J. Martín, “Genetic markers of cardiovascular disease in rheumatoid arthritis,” Mediators of Inflammation, vol. 2012, Article ID 574817, 14 pages, 2012. View at Publisher · View at Google Scholar
  5. P. H. Dessein and A. G. Semb, “Could cardiovascular disease risk stratification and management in rheumatoid arthritis be enhanced?” Annals of the Rheumatic Diseases, vol. 72, no. 11, pp. 1743–1746, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. A. G. Semb, S. Rollefstad, P. van Riel, G. D. Kitas, E. L. Matteson, and S. E. Gabriel, “Cardiovascular disease assessment in rheumatoid arthritis: a guide to translating knowledge of cardiovascular risk into clinical practice,” Annals of the Rheumatic Diseases, vol. 73, no. 7, pp. 1284–1288, 2014. View at Publisher · View at Google Scholar · View at Scopus
  7. J. A. Aviña-Zubieta, H. K. Choi, M. Sadatsafavi, M. Etminan, J. M. Esdaile, and D. Lacaille, “Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies,” Arthritis Care & Research, vol. 59, no. 12, pp. 1690–1697, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. L. Lévy, B. Fautrel, T. Barnetche, and T. Schaeverbeke, “Incidence and risk of fatal myocardial infarction and stroke events in rheumatoid arthritis patients. A systematic review of the literature,” Clinical and Experimental Rheumatology, vol. 26, no. 4, pp. 673–679, 2008. View at Google Scholar · View at Scopus
  9. P. J. Nicola, C. S. Crowson, H. Maradit-Kremers et al., “Contribution of congestive heart failure and ischemic heart disease to excess mortality in rheumatoid arthritis,” Arthritis & Rheumatism, vol. 54, no. 1, pp. 60–67, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. L. A. Trouw, E. M. Haisma, E. W. N. Levarht et al., “Anti-cyclic citrullinated peptide antibodies from rheumatoid arthritis patients activate complement via both the classical and alternative pathways,” Arthritis and Rheumatism, vol. 60, no. 7, pp. 1923–1931, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Kontzias, A. Laurence, M. Gadina, and J. J. O'Shea, “Kinase inhibitors in the treatment of immune-mediated disease,” F1000 Medicine Reports, vol. 4, no. 1, article 5, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. C. J. Sperati, R. S. Parekh, Y. Berthier-Schaad et al., “Association of single-nucleotide polymorphisms in JAK3, STAT4, and STAT6 with new cardiovascular events in incident dialysis patients,” American Journal of Kidney Diseases, vol. 53, no. 5, pp. 845–855, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. P. H. Dessein, A. Solomon, A. J. Woodiwiss, G. R. Norton, L. Tsang, and M. A. Gonzalez-Gay, “Marked independent relationship between circulating interleukin-6 concentrations and endothelial activation in rheumatoid arthritis,” Mediators of Inflammation, vol. 2013, Article ID 510243, 10 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. S. Rollefstad, T. K. Kvien, I. Holme, A. S. Eirheim, T. R. Pedersen, and A. G. P. Semb, “Treatment to lipid targets in patients with inflammatory joint diseases in a preventive cardio-rheuma clinic,” Annals of the Rheumatic Diseases, vol. 72, no. 12, pp. 1968–1974, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. A. G. Semb, T. K. Kvien, D. A. DeMicco et al., “Effect of intensive lipid-lowering therapy on cardiovascular outcome in patients with and those without inflammatory joint disease,” Arthritis and Rheumatism, vol. 64, no. 9, pp. 2836–2846, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. C. D. Popa, E. Arts, J. Fransen, and P. L. C. M. van Riel, “Atherogenic index and high-density lipoprotein cholesterol as cardiovascular risk determinants in rheumatoid arthritis: the impact of therapy with biologicals,” Mediators of Inflammation, vol. 2012, Article ID 785946, 9 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. C. Popa, L. J. H. van Tits, P. Barrera et al., “Anti-inflammatory therapy with tumour necrosis factor alpha inhibitors improves high-density lipoprotein cholesterol antioxidative capacity in rheumatoid arthritis patients,” Annals of the Rheumatic Diseases, vol. 68, no. 6, pp. 868–872, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. A. Solomon, B. F. Christian, G. R. Norton, A. J. Woodiwiss, and P. H. Dessein, “Risk factor profiles for atherosclerotic cardiovascular disease in black and other Africans with established rheumatoid arthritis,” The Journal of Rheumatology, vol. 37, no. 5, pp. 953–960, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. A. Solomon, B. F. Christian, P. H. Dessein, and A. E. Stanwix, “The need for tighter rheumatoid arthritis control in a South African public health care center,” Seminars in Arthritis & Rheumatism, vol. 35, no. 2, pp. 122–131, 2005. View at Publisher · View at Google Scholar · View at Scopus